Clinical Trial Update: Immune Tolerance Induction Study [Phase 4]

View source ↗

Summary

Phase 4 trial update for Immune Tolerance Induction in Pompe disease was terminated with results posted in 2020.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Glycogen Storage Disease Type Ii
• Pompe Disease

Drugs mentioned

• Immune Tolerance Induction Study

Snippet

Sponsor: Genzyme, a Sanofi Company | Conditions: Pompe Disease, Glycogen Storage Disease Type II (GSD-II) | Phase 4 | Status: TERMINATED | Results posted: 2020-10-12